


中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊



CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6

中国新药杂志



23

2017

Vol.26 | No.23

已上市2型糖尿病治疗药物的生殖毒性

口服固体制剂连续生产与过程控制技术研究进展

奇壬醇胃肠吸收及其缓释微丸在比格犬体内的药动学

BACE抑制剂verubecestat的合成

穿山龙总皂苷对痛风性关节炎大鼠血清生物标志物的影响

www.newdrug.cn

ISSN 1003-3734



万方数据

国家食品药品监督管理总局主管



目次

半月刊 1992年创刊

第26卷第23期 2017年12月15日出版

•新药述评与论坛•

- 2753 提高药物研发中心血管毒性的预测性研究进展.....汪巨峰
- 2759 FDA警告信中数据完整性主要问题浅析及启示.....杨祝仁, 赵双春, 赵红菊
- 2764 抗艰难梭菌新药人源型单克隆抗体bezlotoxumab.....李春杏, 刘桦
- 2767 新型肌松拮抗药舒更葡糖.....赵莹, 姜陆洋

•新药申报与审评技术•

- 2772 已上市2型糖尿病治疗药物的生殖毒性.....余珊珊, 尹华静, 周恒, 等

•重大新药创制专项巡礼•

- 2780 口服固体制剂连续生产与过程控制技术研究进展.....仝永涛, 高春红, 高春生
- 2788 奇壬醇胃肠吸收及其缓释微丸在比格犬体内的药动学.....何冬梅, 关世侠, 付宏征, 等

•综述•

- 2794 影响氯吡格雷药效及其代谢的相关因素.....盛国太, 徐秀秀, 葛郁芝
- 2799 阿尔茨海默病的发病机制及天然多酚类化合物的治疗机制研究进展.....刘世贤, 毛林飞, 于凡, 等
- 2805 纳米技术在抗脑中治疗中的应用进展.....梁新童, 李强, 薛明, 等
- 2812 免疫检查点抑制剂临床联合治疗研究进展.....杜萍, 刘丽宏

•临床研究•

- 2818 丁苯酞氯化钠注射液联合依达拉奉治疗新发脑梗死的疗效及神经功能和CRP水平分析.....袁庆芳, 李欣欣, 张剑平, 等
- 2822 红花黄色素改善急性脑梗死患者脑灌注的临床研究.....刘青, 黄德弘, 黄坚红, 等

•复方黄柏液涂剂研究与应用专栏•

- 2826 复方黄柏液涂剂保留灌肠治疗III型前列腺炎临床观察.....祝海, 翁博文, 赵海军, 等
- 2830 复方黄柏液涂剂湿敷治疗湿热下注型肛门湿疹的临床观察.....白克运, 谷超

•实验研究•

- 2834 BACE抑制剂verubecestat的合成.....饶艳, 郭雅俊, 朱雪焱, 等
- 2840 穿山龙总皂苷对痛风性关节炎大鼠血清生物标志物的影响.....林芳芳, 刘树民, 周琦, 等
- 2846 甲氨蝶呤缓释植入剂延迟小鼠肉瘤复发的研究.....刘秀秀, 高莉, 夏伦洋, 等
- 2853 金莲花栓剂的制备及溶出度考察.....翟越, 李媛媛, 王中彦
- 2859 石杉碱甲前体液晶制剂的制备及释放度研究.....郭偲, 周萌萌, 潘倩文, 等
- 2864 环糊精修饰磷酸钙纳米粒递送siRNA用于人非小细胞肺癌细胞模型的实验研究.....裴志杨, 王涛, 陈刚, 等
- 2871 聚乙二醇化多西他赛白蛋白纳米粒用于非小细胞肺癌模型的实验研究.....金光明, 尹学哲, 金明姬, 等

•药物安全与合理应用•

- 2877 北京市医改对于综合医院基本药物使用的影响.....李奕璋

[期刊基本参数] CN11-2850/R*1992*sm*A4*128*zh*P*¥30.00**23*2017-12

责任编辑 王韧 英文审校 魏尔清 杜小莉 李文龙

CONTENTS

CHINESE JOURNAL OF NEW DRUGS

Founded in 1992, Semimonthly
Volume 26, Number 23
December 15, 2017

- 2753 Advance of improvement of the prediction on cardiovascular toxicity in the drug development
WANG Ju-feng
- 2759 Analysis and enlightenment of the main problems of data integrality in FDA warning letters
YANG Zhu-ren, ZHAO Shuang-chun, ZHAO Hong-ju
- 2764 Bezlotoxumab—a new human monoclonal antibody for the prevention of *Clostridium difficile* infection
LI Chun-xing, LIU Hua
- 2767 Sugammadex: a novel selective muscle relaxant antagonist
ZHAO Ying, JIANG Lu-yang
- 2772 Reproductive and developmental toxicity of the marketed anti-diabetic agents for type 2 diabetic mellitus
YU Shan-shan, YIN Hua-jing, ZHOU Heng, *et al*
- 2780 Research progress on continuous production and process control technology of oral solid dosage forms
TONG Yong-tao, GAO Chun-hong, GAO Chun-sheng
- 2788 Absorption mechanism of kirenol and pharmacokinetic analysis of its sustained-release pellets in beagles
HE Dong-mei, GUAN Shi-xia, FU Hong-zheng, *et al*
- 2794 Factors affecting the efficacy of clopidogrel and its metabolism
SHENG Guo-tai, XU Xiu-xiu, GE Yu-zhi
- 2799 Pathogenesis of Alzheimer's disease and the therapeutic mechanism of natural polyphenols
LIU Shi-xian, MAO Lin-fei, YU Fan, *et al*
- 2805 Application progress of nanomedicines in the treatment of stroke
LIANG Xin-tong, LI Qiang, XUE Ming, *et al*
- 2812 Research progress of immune checkpoint inhibitors in clinical treatment
DU Ping, LIU Li-hong
- 2818 Therapeutic effect, nerve function, CRP level analysis of butylphthalide and sodium chloride injection combined with edaravone in the treatment of new-onset cerebral infarction
YUAN Qing-fang, LI Xin-xin, ZHANG Jian-ping, *et al*
- 2822 Clinical study of Safflower yellow pigment on the improving the cerebral perfusion in patients with acute cerebral infarction
LIU Qing, HUANG De-hong, HUANG Jian-hong, *et al*
- 2826 Clinical observation of retention enema with Compound Cortex Phellodendri Ye Paints on type IIIA chronic prostatitis
ZHU Hai, WENG Bo-wen, ZHAO Hai-jun, *et al*
- 2830 Clinical observation of Compound Cortex Phellodendri Fluid wet dressing in the treatment of hot and humid bet type anal eczema
BAI Ke-yun, GU Chao
- 2834 Synthesis of verubecestat as a BACE inhibitor
RAO Yan, GUO Ya-jun, ZHU Xue-yan, *et al*
- 2840 Effects of total saponins from rhizoma dioscorea nipponica on biomarkers in serum of gouty arthritis rats
LIN Fang-fang, LIU Shu-min, ZHOU Qi, *et al*
- 2846 Methotrexate sustained-release implants for delay of sarcoma recurrence in mice
LIU Xiu-xiu, GAO Li, XIA Lun-yang, *et al*
- 2853 Study on preparation and dissolution of troliius suppository
ZHAI Yue, LI Yuan-yuan, WANG Zhong-yan
- 2859 Preparation and release of huperzine A precursor liquid crystal formulations
GUO Si, ZHOU Meng-meng, PAN Qian-wen, *et al*
- 2864 Cyclodextrin-modified calcium phosphate nanoparticles delivering siRNA for the treatment of non-small cell lung cancer cell model
PEI Zhi-yang, WANG Tao, CHEN Gang, *et al*
- 2871 Experimental research on docetaxel loaded PEG-albumin nanoparticles to the situ carcinoma model of non-small cell lung cancer
JIN Guang-ming, YIN Xue-zhe, JIN Ming-ji, *et al*
- 2877 Effects of Beijing health care reform on essential medicine in general hospitals
LI Yi-zhang

Directed by: China Food and Drug Administration

Sponsored by: China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association

Editor-in-Chief: SANG Guo-wei

Board Chairman: SHI Sheng-yi

Edited by: Editorial Board of Chinese Journal of New Drugs

Published by: Chinese Journal of New Drugs Co., Ltd.

Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China

Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>

E-mail: bianjibu@newdrug.cn

Printer: Beijing Kexin Printing Co., Ltd.

Domestic Distribution: Beijing Post Offices

Overseas Distribution: China International Book Trading Corp.
(P.O.Box 399 Beijing, China)

Domestic Subscription: Local Post Offices

Periodical Registration: ISSN 1003-3734 CN 11-2850/R

Publication Date: December 15, 2017

Copyright: 2017 by Chinese Journal of New Drugs Co., Ltd.

凯美纳喜获国家科技进步奖一等奖

EGFR突变的晚期非小细胞肺癌治疗 1 线用药



*Lung Cancer. 2014 Nov;86(2):207-12. doi: 10.1016/j.lungcan.2014.08

- 【药品名称】** 通用名：盐酸埃克替尼片
商品名：凯美纳® Conmana®
- 【适应症】** 本品单药适用于治疗表皮生长因子受体(EGFR)基因具有敏感突变的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗。本品单药可试用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌(NSCLC)，既往化疗主要是指以铂类为基础的联合化疗。详见说明书。
- 【用法用量】** 本品的推荐剂量为每次125mg(1片)，每天三次。口服，空腹或与食物同服，高热量食物可能明显增加药物的吸收。(详见产品说明书)
- 【不良反应】** 最常见不良反应为皮疹、腹泻和氨基转移酶升高，绝大多数为I~II级，一般见于服药后1-3周内，通常是可逆性的，无需特殊处理，可自行消失。
- 【禁忌】** 已知对该活性物质或该产品任一赋形剂有严重过敏反应者。
- 【包装】** 铝塑铝包装。每板21片，每盒装1板。
- 【有效期】** 36个月。

本广告仅供医学、药学专业人士阅读

杭州市余杭经济技术开发区红丰路589号
电话：0571-86130357
网址：www.comana.com

邮政编码：311100
传真：0571-86130266



贝达药业股份有限公司

万方数据 国内定价：30.00元 国内统一刊号CN11-2850/R 邮发代号82-488 国外代号M4240